Summary
MedImmune, LLC (MedImmune), is a biotechnology company operating as the global biologics subsidiary of AstraZeneca. It focuses on the research, development, manufacture and marketing of biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibodies and other next-generation molecules targeting diseasing the areas of oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases. The company’s product portfolio includes products for respiratory syncytial virus; influenza vaccine; and organic thiophosphate cytoprotective agent. The company operates three R&D centers in Gaithersburg, Maryland; Cambridge, the UK; and Mountain View, California. MedImmune is headquartered in Gaithersburg, Maryland, the US.
MedImmune, LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8
MedImmune, LLC, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 9
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 11
MedImmune, LLC, Medical Devices Deals, 2010 to YTD 2016 13
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 14
MedImmune, LLC, Pharmaceuticals & Healthcare, Deal Details 21
Venture Financing 21
G1 Therapeutics Raises USD33 Million in Series B Financing 21
Definiens Raises USD20.3 Million in Venture Financing Round 23
Catabasis Pharma Raises US$32.4 Million In Series B Financing 25
G1 Therapeutics Raises US$12.5 Million In Series A Financing 27
Inotek Pharma Raises US$21 Million In Venture Financing 28
AesRx Raises US$1.35 Million In Venture Financing 30
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 31
Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 33
Definiens Raises US$13 Million In Venture Financing 35
Coferon Raises US$12 Million In Series B Venture Financing Round 37
ADC Therapeutics To Raise US$50 Million In Venture Financing 38
Catabasis Pharma Secures US$8 Million In Extended Series A Financing 40
NeuProtect Secures Second Venture Financing Round 42
Inotek Pharma Raises An Additional US$9.35 Million In Venture Financing 43
Ambit Biosciences Secures US$30 Million In Series D-2 Financing 45
Catabasis Pharma Secures US$14.5 Million In The Second Tranche Of Series A Financing Round 48
Corridor Pharma Secures US$15 Million In Series A Financing 50
VentiRx Pharma Raises US$25 Million In Additional Series A Financing 52
Partnerships 54
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 54
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 55
Cepheid, MedImmune and Combacte Enter into Agreement 57
Rani Therapeutics Enters into Agreement with MedImmune 58
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 59
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 60
MedImmune Enters into Research Agreement with University of Sheffield 61
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 62
MedImmune Enters into Agreement with Juno Therapeutics 63
MedImmune Enters into Research Agreement with Joslin Diabetes Center 64
MedImmune Enters into Research Agreement with COEBP 65
MedImmune Enters into Research Agreement with University of Manchester 66
MedImmune Enters into Co-Development Agreement with National Cancer Institute 67
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 68
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 69
Cancer Research UK Forms Joint Venture with MedImmune 71
Advaxis Enters into Agreement with MedImmune 72
MedImmune Enters Into Research Agreement With Cambridge University 73
MedImmune Enters Into Research Agreement With Johns Hopkins University 74
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 76
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 78
Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 80
PeptiDream Enters into Drug Discovery Agreement with MedImmune 82
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 83
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 85
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 86
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 87
AgonOx Enters Into Co-Development Agreement With MedImmune 88
Pfenex Enters Into Collaboration With MedImmune 89
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 90
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 92
Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 93
Phylogica Enters Into Discovery Collaboration With MedImmune 94
Amplimmune Enters Into Co-Development Agreement With GlaxoSmithKline 95
Licensing Agreements 96
Regeneron Pharma Enters into Licensing Agreement with MedImmune 96
MedImmune Enters into Licensing Agreement with Wacker Biotech 97
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 98
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 99
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 100
MedImmune Enters into Licensing Agreement with Inovio Pharma 101
Shionogi Enters into Licensing Agreement with MedImmune 102
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 103
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 104
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 106
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 108
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 109
MedImmune To Enter Into Licensing Agreement With Pfizer 110
Ligand Pharma Terminates Licensing Agreement With MedImmune 112
Spirogen Enters Into Licensing Agreement With Genentech 113
Immune Design Enters Into Licensing Agreement With MedImmune 115
Xenome Enters Into Licensing Agreement With MedImmune 116
Asset Transactions 117
Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform From MedImmune 117
Acquisition 119
MedImmune Acquires Definiens for USD150 Million 119
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 121
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 123
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 125
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 126
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 129
MedImmune, LLC - Key Competitors 130
Key Employees 131
Locations And Subsidiaries 133
Head Office 133
Other Locations & Subsidiaries 133
Appendix 135
Methodology 135
About GlobalData 135
Contact Us 135
Disclaimer 135
List of Tables
MedImmune, LLC, Pharmaceuticals & Healthcare, Key Facts 1
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8
MedImmune, LLC, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 9
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10
MedImmune, LLC, Deals By Therapy Area, 2010 to YTD 2016 11
MedImmune, LLC, Medical Devices Deals, 2010 to YTD 2016 13
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 14
G1 Therapeutics Raises USD33 Million in Series B Financing 21
Definiens Raises USD20.3 Million in Venture Financing Round 23
Catabasis Pharma Raises US$32.4 Million In Series B Financing 25
G1 Therapeutics Raises US$12.5 Million In Series A Financing 27
Inotek Pharma Raises US$21 Million In Venture Financing 28
AesRx Raises US$1.35 Million In Venture Financing 30
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 31
Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 33
Definiens Raises US$13 Million In Venture Financing 35
Coferon Raises US$12 Million In Series B Venture Financing Round 37
ADC Therapeutics To Raise US$50 Million In Venture Financing 38
Catabasis Pharma Secures US$8 Million In Extended Series A Financing 40
NeuProtect Secures Second Venture Financing Round 42
Inotek Pharma Raises An Additional US$9.35 Million In Venture Financing 43
Ambit Biosciences Secures US$30 Million In Series D-2 Financing 45
Catabasis Pharma Secures US$14.5 Million In The Second Tranche Of Series A Financing Round 48
Corridor Pharma Secures US$15 Million In Series A Financing 50
VentiRx Pharma Raises US$25 Million In Additional Series A Financing 52
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 54
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 55
Cepheid, MedImmune and Combacte Enter into Agreement 57
Rani Therapeutics Enters into Agreement with MedImmune 58
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 59
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 60
MedImmune Enters into Research Agreement with University of Sheffield 61
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 62
MedImmune Enters into Agreement with Juno Therapeutics 63
MedImmune Enters into Research Agreement with Joslin Diabetes Center 64
MedImmune Enters into Research Agreement with COEBP 65
MedImmune Enters into Research Agreement with University of Manchester 66
MedImmune Enters into Co-Development Agreement with National Cancer Institute 67
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 68
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 69
Cancer Research UK Forms Joint Venture with MedImmune 71
Advaxis Enters into Agreement with MedImmune 72
MedImmune Enters Into Research Agreement With Cambridge University 73
MedImmune Enters Into Research Agreement With Johns Hopkins University 74
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 76
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 78
Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 80
PeptiDream Enters into Drug Discovery Agreement with MedImmune 82
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 83
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 85
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 86
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 87
AgonOx Enters Into Co-Development Agreement With MedImmune 88
Pfenex Enters Into Collaboration With MedImmune 89
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 90
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 92
Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 93
Phylogica Enters Into Discovery Collaboration With MedImmune 94
Amplimmune Enters Into Co-Development Agreement With GlaxoSmithKline 95
Regeneron Pharma Enters into Licensing Agreement with MedImmune 96
MedImmune Enters into Licensing Agreement with Wacker Biotech 97
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 98
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 99
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 100
MedImmune Enters into Licensing Agreement with Inovio Pharma 101
Shionogi Enters into Licensing Agreement with MedImmune 102
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 103
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 104
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 106
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 108
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 109
MedImmune To Enter Into Licensing Agreement With Pfizer 110
Ligand Pharma Terminates Licensing Agreement With MedImmune 112
Spirogen Enters Into Licensing Agreement With Genentech 113
Immune Design Enters Into Licensing Agreement With MedImmune 115
Xenome Enters Into Licensing Agreement With MedImmune 116
Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform From MedImmune 117
MedImmune Acquires Definiens for USD150 Million 119
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 121
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 123
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 125
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 126
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 129
MedImmune, LLC, Key Competitors 130
MedImmune, LLC, Key Employees 131
MedImmune, LLC, Other Locations 133
MedImmune, LLC, Subsidiaries 134
List of Figures
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 8
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 9
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 10
MedImmune, LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 11
MedImmune, LLC, Medical Devices Deals, 2010 to YTD 2016 13
